(Obexelimab)Biosimilar Reference Antibody-GS40483 新品

货号：GS40483

Obexelimab (also known as XmAb5871) is an investigational, humanized monoclonal antibody that dually targets CD19 and FcγRIIb. It is engineered with an Fc domain that preferentially binds to the inhibitory receptor FcγRIIb on B cells, while its Fab domain binds to CD19, a B‑cell surface antigen. This dual engagement co‑locates CD19 with FcγRIIb, delivering a potent inhibitory signal that suppresses B‑cell receptor (BCR) signaling and reduces B‑cell activation, proliferation, and antibody production. It is being developed as a B‑cell‑modulating therapy for autoimmune diseases driven by pathogenic B cells and autoantibodies, such as systemic lupus erythematosus (SLE) and IgG4‑related disease (IgG4‑RD).